Predicting survival in chronic lymphocytic leukemia

  title={Predicting survival in chronic lymphocytic leukemia},
  author={Ali Bazargan and Constantine S. Tam and Michael J. Keating},
  journal={Expert Review of Anticancer Therapy},
  pages={393 - 403}
There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglobulin/thymidine kinase; and the most important novel markers include karyotypic aberrations (typically assessed by FISH probes or CpG oligonucleotide karyotyping) and IgVH mutation… 

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.

An analysis of 23 prognostic markers based on prospectively collected data from 1948 CLL patients participating in phase 3 trials of the German CLL Study Group to develop a comprehensive prognostic index with high discriminatory power and prognostic significance on the individual patient level is developed.

Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model

Results of this external comparative validation analysis strongly support the German score as the benchmark for comparison of any novel prognostic scheme aimed at evaluating the TTFT in patients with early CLL even when a modified version which does not include TK is utilized.

High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients

High expression of CD74 was positively correlated with more advanced stage of the disease and no correlation was shown between CD74 and sex, mutational status IgVH and time to first treatment.

Higher percentage of in vitro apoptotic cells at time of diagnosis in patients with chronic lymphocytic leukemia indicate earlier treatment requirement: ten years follow up.

The results of this study emphasize the importance of apoptosis of CLL cells at the time of the initial diagnosis in pathobiology of this disease.

[Clinical characteristics and treatment response in adult patients with non-Hodgkin's chronic lymphocytic leukemia (CLL)].

The chronic lymphocytic leukemia group showed increased survival with lower mortality rate, and Rituximab showed a higher progression-free survival in these neoplasms.

The Role of BCL-2 Family in Clinical Response of Chronic Lymphocytic Leukemia

The relative ratio of Mcl-1 and Bfl-1 to Bcl-2 expression provides a highly significant linear correlation with ABT-737 sensitivity, and the ratio was validated in a panel of leukemic cell lines subjected to genetic and pharmacologic manipulations.

Comparison the Survival Rate of Fludarabine, Chlorambucil and Cyclophosphamide as First-Line Therapy in Patients with Chronic Lymphocytic Leukemia

According to the results of this study, survival and CR were similar between the three arms of the study, but PR was higher in patients received fludarabine.

Characterization of RB1 Deletions in Interphase and Metaphase by Molecular Cytogenetics Exemplified in Chronic Lymphatic Leukemia.

  • T. Liehr
  • Biology
    Methods in molecular biology
  • 2018
The best way how to detect RB1 deletion in CLL is described, with an iFISH diagnostic result with RB 1 deletion as sole aberration is indicative for a favorable course of the disease.



Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.

The results show that s-beta 2M and s-TK independently predict progression-free survival in patients with CLL and IC, and suggest that these prognostic factors may allow an improved prediction of progression- free survival, particularly in early disease stages.

Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance

In 100 untreated patients with chronic lymphocytic leukaemia (CLL) lymphocyte doubling time (LDT) has been investigated in relationship with clinical stages, bone marrow histological patterns, treatment‐free period and survival, and this simple parameter can be useful in the clinical management of CLL patients.

Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia.

Chronic lymphocytic leukemia (CLL) shows a remarkably heterogeneous clinical outcome; survival ranges from several months in advanced stages to more than 10 years in early stages. The Binet and Rai

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

A weighted prognostic model, or nomogram, predictive for overall survival was constructed using the following independent characteristics: age, beta-2 microglobulin, absolute lymphocyte count, sex, Rai stage, and number of involved lymph node groups to help patients and clinicians in clinical decision making as well as in clinical research and clinical trial design.

Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters

A scoring system for overall survival (OS) based on: age ≥65 years, WBC ≥20 × 109/l, unmutated IgVH status, TP53 deletion, t(IgH), and the number of chromosome aberrations observed with CBA is proposed.

Prospective Evaluation of Prognostic Parameters in Early Stage Chronic Lymphocytic Leukemia (CLL): Results of the CLL1-Protocol of the German CLL Study Group (GCLLSG).

This prospective trial defined clinical and biological factors (TK, LDT, beta-2-MG, absolute lymphocyte count, age, sex) which help to predict progression in early CLL and its model for risk stratification reliably separated between HR and LR.

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease

There is an increasing consensus for screening for TP53 abnormalities in CLL patients who fulfil the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) recommendations for initiating therapy.

Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL

A higher serum thymidine kinase level proved to be a strong predictor of mutational status, and the only independent one among the studied parameters, suggesting that s-TK level could be used routinely to identify patients at risk of progression.

Bone marrow histologic pattern--the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases.

BM histologic pattern appears to be a better single prognostic parameter than any one of the variables employed in current clinical staging systems, and a combined clinicopathologic system incorporating the BM pattern is presented.